Real-world outcomes of radium-223 dichloride for metastatic castration resistant prostate cancer

被引：33

作者：

Kuppen, Malou C. P. ^{[1
]}

Westgeest, Hans M. ^{[2
]}

van der Doelen, Maarten J. ^{[3
]}

van den Eertwegh, Alphonsus J. M. ^{[4
]}

Coenen, Jules L. L. M. ^{[5
]}

Aben, Katja K. H. ^{[6
,7
]}

van den Bergh, Alphons C. M. ^{[8
]}

Bergman, Andries M. ^{[9
]}

van den Bosch, Joan ^{[10
]}

Celik, Filiz ^{[11
]}

Hendriks, Mathijs P. ^{[12
]}

Lavalaye, Jules ^{[13
]}

van der Meer, Saskia ^{[14
]}

Polee, Marco B. ^{[15
]}

Somford, Diederik M. ^{[16
]}

van Oort, Inge M. ^{[17
]}

Uyl-de Groot, Carin A. ^{[1
]}

Gerritsen, Winald R. ^{[3
]}

机构：

[1] Erasmus Univ, Erasmus Sch Hlth Policy & Management, Inst Med Technol Assessment, Rotterdam, Netherlands

[2] Amphia Hosp, Dept Internal Med, Breda, Netherlands

[3] Radboud Univ Nijmegen, Dept Med Oncol, Med Ctr, Nijmegen, Netherlands

[4] Vrije Univ, Canc Ctr Amsterdam, Dept Med Oncol, Amsterdam UMC, Amsterdam, Netherlands

[5] Isala, Dept Oncol, Zwolle, Netherlands

[6] Radboud Univ Nijmegen, Dept Hlth Evidence, Med Ctr, Nijmegen, Netherlands

[7] Netherlands Comprehens Canc Org, Utrecht, Netherlands

[8] Univ Med Ctr Groningen, Dept Radiat Oncol, Groningen, Netherlands

[9] Netherlands Canc Inst, Div Internal Med MOD & Oncogen, Antoni van Leeuwenhoek Hosp, Amsterdam, Netherlands

[10] Albert Schweitzer Ziekenhuis, Dept Internal Med, Dordrecht, Netherlands

[11] Deventer Hosp, Dept Nucl Med, Deventer, Netherlands

[12] Northwest Clin, Dept Internal Med, Alkmaar, Netherlands

[13] St Antonius Hosp, Dept Nucl Med, Nieuwegein, Netherlands

[14] Jeroen Bosch Hosp, Dept Urol, sHertogenbosch, Netherlands

[15] Med Ctr Leeuwarden, Dept Internal Med, Leeuwarden, Netherlands

[16] Canisius Wilhelmina Hosp, Dept Urol, Nijmegen, Netherlands

[17] Radboud Univ Nijmegen, Dept Urol, Med Ctr, Nijmegen, Netherlands

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 19期

关键词：

metastatic castration-resistant prostate cancer; radium-223; real-world outcomes; sequencing; skeletal-related events; survival; BONE METASTASES; DOUBLE-BLIND; THERAPY; PHASE-3; TRIAL; RECOMMENDATIONS; EXPERIENCE; EFFICACY; EVENTS; CYCLES;

D O I：

10.2217/fon-2020-0039

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Timing of radium-223 (Ra-223) in metastatic castration-resistant prostate cancer (mCRPC) remains challenging due to alternative options and short window of opportunity. Methods: Ra-223 treated patients in the CAPRI-registry were included. Outcomes were evaluated based on treatment line of Ra-223. Results: Out of 285 patients, 49% received Ra-223 in line >= 3. 51% completed six Ra-223 injections and 34% had a symptomatic skeletal event after first Ra-223 without differences between subgroups. After correction of known prognostic factors Ra-223 in line >= 3 (HR: 3.267; 95% CI: 1.689-6.317; p < 0.01) remained associated with worse OS. Conclusion: In the Netherlands, Ra-223 was mainly started as second or third mCRPC-treatment in 2014-2018. Later timing of Ra-223 did affect OS, but not treatment completion and occurrence of symptomatic skeletal events.

引用

页码：1371 / 1384

页数：14

共 50 条

[21] The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer
Heinrich, Daniel
Bektic, Jasmin
Bergman, Andries M.
Caffo, Orazio
Cathomas, Richard
Chi, Kim N.
Daugaard, Gedske
Keizman, Daniel
Kindblom, Jon
Kramer, Gero
Olmos, David
Omlin, Aurelius
Sridhar, Srikala S.
Tucci, Marcello
van Oort, Inge
Nilsson, Sten
CLINICAL GENITOURINARY CANCER, 2018, 16 (01) : E223 - E231
[22] Treatment intensification with radium-223 plus enzalutamide in patients with metastatic castration-resistant prostate cancer
Shore, Neal
Carles, Joan
McDermott, Ray
Agarwal, Neeraj
Tombal, Bertrand
FRONTIERS IN MEDICINE, 2024, 11
[23] Alpha emitter radium-223 in patients with metastatic castration-resistant prostate cancer: A cost-utility analysis
Zeng, Xiaohui
Liu, Qiao
Tan, Chongqing
Wan, Xiaomin
Wang, Yunhua
Ma, Xiaowei
FRONTIERS IN PHARMACOLOGY, 2022, 13
[24] Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer
Du, Yong
Carrio, Ignasi
De Vincentis, Giuseppe
Fanti, Stefano
Ilhan, Harun
Mommsen, Caroline
Nitzsche, Egbert
Sundram, Francis
Vogel, Wouter
Oyen, Wim
Lewington, Val
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2017, 44 (10) : 1671 - 1678
[25] A Phase lb Study of Atezolizumab with Radium-223 Dichloride in Men with Metastatic Castration-Resistant Prostate Cancer
Fong, Lawrence
Morris, Michael J.
Sartor, Oliver
Higano, Celestia S.
Pagliaro, Lance
Alva, Ajjai
Appleman, Leonard J.
Tan, Winston
Vaishampayan, Ulka
Porcu, Raphaelle
Tayama, Darren
Kadel, Edward E., III
Yuen, Kobe C.
Datye, Asim
Armstrong, Andrew J.
Petrylak, Daniel P.
CLINICAL CANCER RESEARCH, 2021, 27 (17) : 4746 - 4756
[26] Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Peters, Michel L.
de Meijer, Claudine
Wyndaele, Dirk
Noordzij, Walter
Leliveld-Kors, Annemarie M.
van den Bosch, Joan
van den Berg, Pieter H.
Baka, Agni
Gaultney, Jennifer G.
APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (01) : 133 - 143
[27] Real World Outcomes in Patients With Metastatic, Castration-Resistant Prostate Cancer Treated With Radium-223 in Routine Clinical Practice in Sweden
Stattin, Par
Westerberg, Marcus
Lissbrant, Ingela Franck
Eriksson, Marie Hjalm
Kjellman, Anders
Ullen, Anders
Vassilev, Zdravko
Sandstrom, Per
Weinrib, Rachel
Martinez, David
Garcia-Albeniz, Xabier
CLINICAL GENITOURINARY CANCER, 2023, 21 (01) : 107.e1 - 107.e9
[28] Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer
Armstrong, Andrew J.
Gupta, Santosh
Healy, Patrick
Kemeny, Gabor
Leith, Beth
Zalutsky, Michael R.
Spritzer, Charles
Davies, Catrin
Rothwell, Colin
Ware, Kathryn
Somarelli, Jason A.
Wood, Kris
Ribar, Thomas
Giannakakou, Paraskevi
Zhang, Jiaren
Gerber, Drew
Anand, Monika
Foo, Wen-Chi
Halabi, Susan
Gregory, Simon G.
George, Daniel J.
PLOS ONE, 2019, 14 (05):
[29] Radium-223 in the therapeutic sequence of metastatic castration-resistant prostate cancer
Unda-Urzaiz, M.
Sousa-Campo, R.
Rodriguez-Antolin, A.
Silva-Marins, C.
Juarez-Soto, A.
Minana-Lopez, B.
Figueiredo-de Castro, A.
Cozar-Olmos, J. M.
ACTAS UROLOGICAS ESPANOLAS, 2018, 42 (04): : 227 - 237
[30] Treatment outcomes with radium-223 in docetaxel-naive versus docetaxel-treated metastatic castration-resistant prostate cancer patients: Real-world evidence from Taiwan
Chiang, Ping-Chia
Chiang, Po-Hui
Chen, I-Hsuan Alan
Chen, Yen-Ta
Wang, Hung-Jen
Cheng, Yuan-Tso
Kang, Chih-Hsiung
Chen, Chien-Hsu
Liu, Yi-Yang
Su, Yu-Li
Chen, Yen-Hao
Luo, Hao-Lun
MEDICINE, 2023, 102 (05) : E32671

← 1 2 3 4 5 →